Cytori Therapeutics Inc  

(Public, NASDAQ:CYTX)   Watch this stock  
Find more results for CYTX
2.03
-0.02 (-0.98%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.03 - 2.09
52 week 1.91 - 7.93
Open 2.06
Vol / Avg. 0.00/155,806.00
Mkt cap 397.53M
P/E 11.43
Div/yield     -
EPS 0.18
Shares 13.33M
Beta 2.55
Inst. own 15%
Aug 4, 2016
Q2 2016 Cytori Therapeutics Inc Earnings Call - 5:30PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Cytori Therapeutics Inc Earnings Release - 4:15PM EDT - Add to calendar
May 10, 2016
Q1 2016 Cytori Therapeutics Inc Earnings Call
May 10, 2016
Q1 2016 Cytori Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -182.97% -160.77%
Operating margin -174.67% -133.34%
EBITD margin - -187.50%
Return on average assets -60.65% -49.06%
Return on average equity -214.69% -596.71%
Employees 80 -
CDP Score - -

Address

3020 Callan Rd
SAN DIEGO, CA 92121-1109
United States - Map
+1-858-4580900 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Officers and directors

David M. Rickey Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Marc H. Hedrick M.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Tiago Girao Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
Age: 35
Bio & Compensation  - Reuters
Seijiro N. Shirahama President , Asia Pacific
Age: 60
Bio & Compensation  - Reuters
Steven Kesten Executive Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
John David Harris Vice President, General Manager - Cell Therapy
Bio & Compensation  - Reuters
Jeremy Bragg Hayden Vice President - Business Development, General Counsel
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters
Paul W. Hawran CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 56
Bio & Compensation  - Reuters